Prudential Financial Inc. Grows Stock Position in ICU Medical, Inc. (NASDAQ:ICUI)

Prudential Financial Inc. boosted its position in ICU Medical, Inc. (NASDAQ:ICUI) by 7.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 82,059 shares of the medical instruments supplier’s stock after buying an additional 5,795 shares during the period. Prudential Financial Inc. owned approximately 0.34% of ICU Medical worth $12,733,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Barclays PLC lifted its stake in shares of ICU Medical by 15.6% in the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after acquiring an additional 8,010 shares during the period. Principal Financial Group Inc. lifted its position in ICU Medical by 24.6% in the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock valued at $23,130,000 after purchasing an additional 25,031 shares during the period. MetLife Investment Management LLC boosted its holdings in ICU Medical by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier’s stock valued at $2,258,000 after purchasing an additional 6,981 shares in the last quarter. Jennison Associates LLC acquired a new position in ICU Medical during the 4th quarter worth approximately $556,000. Finally, Geode Capital Management LLC raised its stake in shares of ICU Medical by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after buying an additional 48,106 shares in the last quarter. 96.10% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Vivek Jain sold 1,373 shares of ICU Medical stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at $16,262,119.64. The trade was a 1.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 6.70% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on ICUI shares. StockNews.com lowered ICU Medical from a “buy” rating to a “hold” rating in a report on Thursday. Jefferies Financial Group raised shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price target on the stock in a research note on Wednesday, December 11th. Finally, Raymond James set a $97.00 price objective on shares of ICU Medical in a research note on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $168.67.

ICU Medical Stock Down 3.0 %

ICUI opened at $144.28 on Friday. ICU Medical, Inc. has a one year low of $93.36 and a one year high of $196.26. The company has a market cap of $3.54 billion, a price-to-earnings ratio of -31.57 and a beta of 0.73. The business’s fifty day moving average is $154.89 and its two-hundred day moving average is $164.01. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.